Marrone Bio Innovations (MBII) 10-Q15 May 142014 Q1 Quarterly reportFinancial data

Company Profile

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
Document and Entity Information	Mar. 31, 2014	8-May-14
Document And Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	31-Mar-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q1	'
Trading Symbol	'MBII	'
Entity Registrant Name	'MARRONE BIO INNOVATIONS INC	'
Entity Central Index Key	'0001441693	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Non-accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	19,751,273

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013
Current assets:	'	'
Cash and cash equivalents	$21,298	$24,455
Short-term investments	2,664	13,677
Accounts receivable	7,231	6,215
Accounts receivable from related parties	1,230	903
Inventories, net	12,837	11,666
Prepaid expenses and other current assets	1,765	1,737
Total current assets	47,025	58,653
Property, plant and equipment, net	15,795	9,420
Other assets	639	806
Total assets	63,459	68,879
Current liabilities:	'	'
Accounts payable	8,563	4,460
Accrued liabilities	3,040	4,380
Deferred revenue, current portion	1,017	1,209
Deferred revenue from related parties, current portion	31	131
Capital lease obligations, current portion	1,680	1,401
Debt, current portion	123	157
Total current liabilities	14,454	11,738
Deferred revenue, less current portion	695	744
Deferred revenue from related parties, less current portion	404	628
Capital lease obligations, less current portion	1,059	1,134
Debt, less current portion	12,312	12,280
Other liabilities	574	571
Total liabilities	29,498	27,095
Commitments and contingencies (Note 12)	'	'
Stockholders' equity:	'	'
Preferred stock: $0.00001 par value; 20,000 shares authorized, no shares issued or outstanding at March 31, 2014 and December 31, 2013	'	'
Common stock: $0.00001 par value; 250,000 shares authorized and 19,707 and 19,323 shares issued and outstanding at March 31, 2014 and December 31, 2013, respectively	'	'
Additional paid in capital	149,643	147,220
Accumulated deficit	-115,682	-105,436
Total stockholders' equity	33,961	41,784
Total liabilities and stockholders' equity	$63,459	$68,879

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013
Statement Of Financial Position [Abstract]	'	'
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	20,000	20,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	250,000	250,000
Common stock, shares issued	19,707	19,323
Common stock, shares outstanding	19,707	19,323

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Revenues:	'	'
Product	$2,097	$2,373
License	45	48
Related party	648	309
Total revenues	2,790	2,730
Cost of product revenues, including cost of product revenues to related parties of $192 and $194 for the three months ended March 31, 2014 and 2013, respectively	1,652	1,795
Gross profit	1,138	935
Operating expenses:	'	'
Research, development and patent	4,282	3,283
Selling, general and administrative	6,330	2,847
Total operating expenses	10,612	6,130
Loss from operations	-9,474	-5,195
Other income (expense):	'	'
Interest income	10	1
Interest expense	-773	-1,985
Change in estimated fair value of financial instruments	'	-3,563
Other expense, net	-9	-7
Total other expense, net	-772	-5,554
Loss before income taxes	-10,246	-10,749
Income taxes	'	'
Net loss	($10,246)	($10,749)
Net loss per common share:	'	'
Basic and diluted	($0.52)	($8.48)
Weighted-average shares outstanding used in computing net loss per common share:	'	'
Basic and diluted	19,518	1,268

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Operations (Parenthetical) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Income Statement [Abstract]	'	'
Cost of product revenues to related parties	$192	$194

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements of Comprehensive Loss (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Amounts Reclassified Out Of Accumulated Other Comprehensive Income Loss [Abstract]	'	'
Net loss	($10,246)	($10,749)
Other comprehensive loss	'	'
Comprehensive loss	($10,246)	($10,749)

Condensed_Consolidated_Stateme3

Condensed Consolidated Statements of Cash Flows (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Cash flows from operating activities	'	'
Net loss	($10,246)	($10,749)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation and amortization	488	184
Share-based compensation	1,522	249
Non-cash interest expense	248	1,467
Change in estimated fair value of financial instruments	'	3,563
Amortization of investment securities premiums/discounts, net	9	'
Net changes in operating assets and liabilities:	'	'
Accounts receivable	-1,016	59
Accounts receivable from related parties	-327	-132
Inventories	-1,171	-495
Prepaid expenses and other assets	-224	-558
Accounts payable	2,737	138
Accrued and other liabilities	-1,337	-1,320
Deferred revenue	-241	-48
Deferred revenue from related parties	-324	-33
Net cash used in operating activities	-9,882	-7,675
Cash flows from investing activities	'	'
Purchases of property, plant and equipment	-5,044	-432
Purchase of short-term investments	-49	'
Maturities of short-term investments	11,053	'
Net cash provided by (used in) investing activities	5,960	-432
Cash flows from financing activities	'	'
Repayment of debt	-67	-9,224
Repayment of capital leases	-69	-25
Change in restricted cash	'	9,139
Proceeds from exercise of stock options	851	2
Proceeds from exercise of common stock warrants	50	'
Net cash provided by (used in) financing activities	765	-108
Net decrease in cash and cash equivalents	-3,157	-8,215
Cash and cash equivalents, beginning of year	24,455	10,006
Cash and cash equivalents, end of period	21,298	1,791
Supplemental disclosure of cash flow information	'	'
Cash paid for interest, net of capitalized interest of $469 and $113 for the three months ended March 31, 2014 and 2013, respectively	525	518
Supplemental disclosure of non-cash investing and financing activities	'	'
Property, plant and equipment included in accounts payable and accrued liabilities	2,040	'
Equipment acquired under capital leases	453	77
Interest added to the principal of convertible notes	'	$628

Condensed_Consolidated_Stateme4

Condensed Consolidated Statements of Cash Flows (Parenthetical) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Statement Of Cash Flows [Abstract]	'	'
Cash paid for interest, net of capitalized interest	$469	$113

Summary_of_Business

Summary of Business	3 Months Ended
Summary of Business	Mar. 31, 2014
Accounting Policies [Abstract]	'
Summary of Business	'
	1. Summary of Business
	Marrone Bio Innovations, Inc. (Company), formerly Marrone Organic Innovations, Inc., was incorporated under the laws of the State of Delaware on June 15, 2006, and is located in Davis, California. In July 2012, the Company formed a wholly-owned subsidiary, Marrone Michigan Manufacturing LLC (MMM LLC), which holds the assets of a manufacturing plant the Company purchased in July 2012 (See Note 2). The Company makes bio-based pest management and plant health products. The Company targets the major markets that use conventional chemical pesticides, including certain agricultural and water markets where its bio-based products are used as substitutes for, or in connection with, conventional chemical pesticides. The Company also targets new markets for which there are no available conventional chemical pesticides, the use of conventional chemical pesticides may not be desirable or permissible, or the development of pest resistance has reduced the efficacy of conventional chemical pesticides. The Company delivers EPA-approved and registered biopesticide products and other bio-based products that address the global demand for effective, safe and environmentally responsible products.
	The Company is an early stage company with a limited operating history and has only recently begun commercializing its products. As of March 31, 2014, the Company had an accumulated deficit of $115,682,000 and expects to continue to incur losses for the foreseeable future. Until the Company’s initial public offering (IPO) in August 2013, the Company had funded operations primarily with the net proceeds from the private placements of convertible preferred stock, convertible notes, promissory notes, term loans, as well as proceeds from the sale of its products and payments under strategic collaboration agreements and government grants. The Company will need to generate significant revenue to achieve and maintain profitability. As of March 31, 2014, the Company had working capital of $32,571,000 and cash, cash equivalents and short-term investments of $23,962,000.
	On August 1, 2013, the Company amended and restated its certificate of incorporation to effect a reverse split of shares of its common stock at a 1-for-3.138458 ratio (See Note 13).
	The Company participates in a heavily regulated and highly competitive crop protection industry and believes that adverse changes in any of the following areas could have a material effect on the Company’s future financial position, results of operations, or cash flows: inability to obtain regulatory approvals, increased competition in the pesticide market, market acceptance of the Company’s products, weather and other seasonal factors beyond the Company’s control, the Company’s ability to support increased growth and litigation or claims against the Company based on intellectual property, patent, product, regulatory or other factors.

Significant_Accounting_Policie

Significant Accounting Policies

3 Months Ended

Mar. 31, 2014

Accounting Policies [Abstract]

Significant Accounting Policies

2. Significant Accounting Policies

Basis of Presentation

The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All significant intercompany balances and transactions have been eliminated in consolidation.

The accompanying financial information as of March 31, 2014 and for the three months ended March 31, 2014 and 2013 have been prepared by the Company, without audit, in accordance with generally accepted accounting principles in the United States (GAAP) and applicable rules and regulations of the Securities and Exchange Commission regarding interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. However, the Company believes that the disclosures are adequate to make the information presented not misleading. The information included in this quarterly report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2013.

In the opinion of management, the condensed consolidated financial statements as of March 31, 2014 and for the three months ended March 31, 2014 and 2013 reflect all adjustments, which are normal recurring adjustments, necessary to present a fair statement of financial position, results of operations, comprehensive loss and cash flows. The results of operations for the three months ended March 31, 2014 are not necessarily indicative of the operating results for the full fiscal year or any future periods.

Use of Estimates

Conformity with GAAP requires the use of estimates and judgments that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. These estimates are based on management’s knowledge about current events and expectations about actions we may undertake in the future. Actual results could differ materially from those estimates.

Reclassifications

Certain prior period amounts have been reclassified to conform to the current year presentation. These reclassifications have no effect on previously reported net income.

Cash and Cash Equivalents

The Company considers all highly liquid financial instruments purchased with a maturity of three months or less to be cash equivalents. Cash and cash equivalents consist of cash on deposit, money market funds and certificates of deposit accounts (CDs) with U.S. financial institutions. The Company is exposed to credit risk in the event of default by financial institutions to the extent that cash and cash equivalents balances with financial institutions are in excess of amounts that are insured by the Federal Deposit Insurance Corporation. The Company has not experienced any losses on these deposits.

Short-Term Investments

The Company’s short-term investments consist of certificates of deposit with original maturities less than one year but greater than three months which are classified as held-to-maturity. Certificates of deposit are stated at their amortized cost with realized gains or losses, if any, reported as other income or expenses in the condensed consolidated statements of operations. The Company routinely evaluates the realizability of its short-term investments and recognizes an impairment charge when a decline in the estimated fair value of a short-term investment is below the amortized cost and determined to be other-than-temporary. The Company considers various factors in determining whether to recognize an impairment charge, including the duration of time and the severity to which the fair value has been less than amortized cost, any adverse changes in the investee’s financial condition, and the Company’s intent and ability to hold the short-term investment for a period of time sufficient to allow for any anticipated recovery in market value. To date, the Company has not recognized any losses on its short-term investments.

Concentration of Credit Risk

Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, short-term investments, accounts receivable and debt. The Company deposits its cash, cash equivalents and short-term investments with high credit quality domestic financial institutions with locations in the U.S. Such deposits may exceed federal deposit insurance limits. The Company believes the financial risks associated with these financial instruments are minimal.

The Company’s customer base is dispersed across many different geographic areas, and currently most customers are pest management distributors in the U.S. Generally, receivables are due up to 120 days from the invoice date and are considered past due after this date, although the Company may offer extended terms from time to time.

For the three months ended March 31, 2014 and 2013, 5% and 14%, respectively, of the Company’s revenues were generated from international customers.

The Company’s principal sources of revenues are its Regalia and Grandevo product lines. For the three months ended March 31, 2014 and 2013, 87% and 97%, respectively, of the Company’s revenues were generated from sales of Grandevo and Regalia.

Customers with 10% or more of the Company’s total revenues consist of the following:

CUSTOMER

C (1)

For the three months ended March 31,

2014

2013

Represents less than 10% of total revenues

(1)

Represents related party revenues. See Note 14 for further discussion.

Customers with 10% or more of the Company’s outstanding accounts receivable consist of the following:

CUSTOMER

B (1)

March 31, 2014

December 31, 2013

(1)

Represents accounts receivable from related parties. See Note 14 for further discussion.

Inventories

Inventories are stated at the lower of cost or market value (net realizable value or replacement cost) and include the cost of material and external labor and manufacturing costs. Cost is determined on the first-in, first-out basis. The Company provides for inventory reserves when conditions indicate that the selling price may be less than cost due to physical deterioration, obsolescence, changes in price levels, or other factors. Additionally, the Company provides reserves for excess and slow-moving inventory on hand that is not expected to be sold to reduce the carrying amount of excess slow-moving inventory to its estimated net realizable value. The reserves are based upon estimates about future demand from the Company’s customers and distributors and market conditions. As of March 31, 2014 and December 31, 2013, the Company had $45,000 in reserves against its inventories.

Deferred Cost of Product Revenues

Deferred cost of product revenues are stated at the lower of cost or net realizable value and include product sold where title has transferred but the criteria for revenue recognition have not been met. As of March 31, 2014 and December 31, 2013, the Company had $308,000 and $418,000, respectively, of current deferred cost of product revenues, which is included in prepaid expenses and other current assets in the condensed consolidated balance sheets.

Acquisition

On July 19, 2012 (Acquisition Date), the Company purchased land, a building and equipment (Manufacturing Plant) for $1,459,000, including $341,000 of transaction costs. The Manufacturing Plant is located in Bangor, Michigan. Prior to the acquisition, the Manufacturing Plant was owned by a bank and sold in a foreclosure auction. Accordingly, the purchase price for the Manufacturing Plant was less than the estimated fair value of the assets acquired by $257,000. The excess of fair value of the assets acquired over the purchase price was allocated on a relative fair value basis to all assets acquired. The acquisition of the Manufacturing Plant will allow the Company to manufacture certain products internally and improve the overall operating efficiencies and margins of the business as the production of these products historically has been outsourced.

The acquisition was accounted for as an asset acquisition in accordance with ASC 805, Business Combinations (ASC 805). The assets acquired under the Manufacturing Plant acquisition have been included in the Company’s condensed consolidated financial statements from the Acquisition Date. The purchase price was allocated to assets acquired as of the Acquisition Date.

Prior to the allocation of the excess of fair value of the assets acquired over the purchase price, the assets acquired are first measured at their fair values. The Company engaged a third-party valuation firm to assist with its estimated fair value of the assets acquired. The following methods and assumptions are used to estimate the fair value of each class of asset acquired:

Land—Market approach based on similar, but not identical, transactions in the market. Adjustments to comparable sales are based on both the quantitative and qualitative data.

Building—The cost approach, market approach and income approach were used to assess fair value. Cost approach is based on replacement cost new less depreciation adjusted for physical deterioration, functional obsolescence and external/economic obsolescence, as applicable. The market approach is based on similar, but not identical, transactions in the market using both quantitative and qualitative data. The income approach is based on the direct capitalization method using similar but not identical lease rates and making an assessment of net operating income.

Equipment—Both the cost approach and the market approach were used to assess fair value. Cost approach is based on replacement cost new less depreciation adjusted for physical deterioration, functional obsolescence and external/economic obsolescence, as applicable. The market approach is based on similar, but not identical, transactions in the market using both quantitative and qualitative data.

The following table summarizes the estimated fair value of the assets acquired as of the Acquisition Date, which were determined using Level 2 and 3 inputs as described above (in thousands):

JULY 19,

2012

Land

Building

314

Equipment

1,144

Assets acquired

1,459

As the Manufacturing Plant had not yet been placed in full service as of March 31, 2014, the assets acquired, except the land, were recorded as construction in progress as a component of property, plant and equipment in the accompanying condensed consolidated balance sheets as of March 31, 2014 and December 31, 2013. In addition, interest expense in the amount of $1,271,000 and $801,000 was recorded in construction in progress as of March 31, 2014 and December 31, 2013, respectively.

Revenue Recognition

The Company recognizes revenues when persuasive evidence of an arrangement exists, delivery and transfer of title has occurred or services have been rendered, the price is fixed or determinable, and collectability is reasonably assured, unless contractual obligations, acceptance provisions or other contingencies exist. If such obligations or provisions exist, revenue is recognized after such obligations or provisions are fulfilled or expire.

Product revenues consist of revenues generated from sales to distributors and from sales of the Company’s products to direct customers, net of rebates and cash discounts. For sales of products made to distributors, the Company considers a number of factors in determining whether revenue is recognized upon transfer of title to the distributor, or when payment is received. These factors include, but are not limited to, whether the payment terms offered to the distributor in comparison to the Company’s historical terms are considered to be longer than normal payment terms, the distributor history of adhering to the terms of its contractual arrangements with the Company, whether the Company has a pattern of granting concessions for the benefit of the distributor, and whether there are other conditions that may indicate that the sale to the distributor is not substantive. When the Company offers payment terms that are considered to be extended in comparison to the Company’s historical terms, the Company considers the arrangement not to be fixed or determinable, and accordingly, revenue is deferred until payment is due. The costs associated with such deferral are also deferred and classified in prepaid expenses and other current assets in the condensed consolidated balance sheets. The Company currently recognizes revenue primarily on the sell-in method with its distributors. Distributors generally do not have price protection or return rights.

As of March 31, 2014 and December 31, 2013, the Company had current deferred product revenues of $824,000 and $1,016,000, respectively.

From time to time, the Company offers certain product rebates, which are recorded as reductions to product revenues. An accrued liability for these product rebates is recorded at the time the revenues are recorded.

The Company recognizes license revenues pursuant to strategic collaboration and distribution agreements under which the Company receives payments for the achievement of testing validation, regulatory progress and commercialization events. As these activities and payments are associated with exclusive rights that the Company provides in connection with strategic collaboration and distribution agreements over the term of the agreements, revenues related to the payments received are deferred and recognized over the term of the exclusive distribution period of the respective agreement. No payments were received under these agreements during the three months ended March 31, 2014 and 2013. For the three months ended March 31, 2014 and 2013, the Company recognized $45,000 and $48,000, respectively, as license revenues in the accompanying condensed consolidated statements of operations.

For the three months ended March 31, 2014 and 2013, the Company recognized $328,000 and $33,000 of related party revenues under these agreements, respectively, based on the terms of the Company’s agreements with Syngenta, an affiliate of one of our 5% stockholders, of which, $292,000 was recognized during the three months ended March 31, 2014 upon the termination of one of these agreements.

At March 31, 2014, the Company recorded current and non-current deferred revenues of $224,000 and $1,099,000, respectively, related to payments received under these agreements, of which $31,000 and $404,000, respectively, related to deferred revenues from related parties based on the terms of the Company’s commercial agreement with Syngenta. At December 31, 2013, the Company recorded current and non-current deferred revenues of $324,000 and $1,372,000, respectively, related to payments received under these agreements, of which $131,000 and $628,000, respectively, related to deferred revenues from related parties based on the terms of the Company’s agreements with Syngenta.

Research, Development and Patent Expenses

Research and development expenditures, which primarily consist of payroll-related expenses, toxicology costs, regulatory costs, consulting costs and lab costs, and patent expenses, which primarily consist of legal costs relating to the patents and patent filing costs, are expensed to operations as incurred. For the three months ended March 31, 2014 and 2013, research and development expenses totaled $3,985,000 and $3,064,000, respectively, and patent expenses totaled $297,000 and $219,000, respectively.

Recently Issued Accounting Pronouncements

There have been no new accounting pronouncements issued during the three months ended March 31, 2014 that are of significance, or potential significance, to the Company.

Fair_Value_Measurements

Fair Value Measurements

3 Months Ended

Mar. 31, 2014

Fair Value Disclosures [Abstract]

Fair Value Measurements

3. Fair Value Measurements

ASC 820, Fair Value Measurements (ASC 820), clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability.

ASC 820 requires that the valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. ASC 820 establishes a three tier value hierarchy, which prioritizes inputs that may be used to measure fair value as follows:

•

Level 1—Quoted prices in active markets for identical assets or liabilities.

•

Level 2—Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

•

Level 3—Inputs that are generally unobservable and typically reflect management’s estimate of assumptions that market participants would use in pricing the asset or liability.

The following table presents the Company’s financial assets and liabilities measured at fair value on a recurring basis as of March 31, 2014 and December 31, 2013 (in thousands):

31-Mar-14

TOTAL

LEVEL 1

LEVEL 2

LEVEL 3

Assets

Money market funds

5,069

—

DECEMBER 31, 2013

TOTAL

LEVEL 1

LEVEL 2

LEVEL 3

Assets

Money market funds

16,268

—

The money market funds held as of March 31, 2014, and December 31, 2013, were in active markets and, therefore, are measured based on the Level 1 valuation hierarchy.

ShortTerm_Investments

Short-Term Investments

3 Months Ended

Mar. 31, 2014

Investments Debt And Equity Securities [Abstract]

Short-Term Investments

4. Short-Term Investments

The Company’s short-term investments consist of certificates of deposit with original maturities less than one year but greater than three months which are classified as held-to-maturity. Certificates of deposit are stated at their amortized cost with realized gains or losses, if any, reported as other income or expenses in the consolidated statements of operations. The Company routinely evaluates the realizability of its short-term investments and recognizes an impairment charge when a decline in the estimated fair value of a short-term investment is below the amortized cost and determined to be other-than-temporary. The Company considers various factors in determining whether to recognize an impairment charge, including the duration of time and the severity to which the fair value has been less than amortized cost, any adverse changes in the investee’s financial condition, and the Company’s intent and ability to hold the short-term investment for a period of time sufficient to allow for any anticipated recovery in market value. To date, the Company has not recognized any losses on its short-term investments.

The amortized cost and estimated fair values of short-term investments are summarized in the following table (in thousands):

MARCH 31, 2014

AMORTIZED

GROSS

ESTIMATED

COST

UNREALIZED

FAIR VALUE

GAINS

LOSSES

Securities Held-to-Maturity

Certificates of deposit, with maturities less than 1 year

2,664

—

2,664

DECEMBER 31, 2013

AMORTIZED

GROSS

ESTIMATED

COST

UNREALIZED

FAIR VALUE

GAINS

LOSSES

Securities Held-to-Maturity

Certificates of deposit, with maturities less than 1 year

13,677

—

)

13,673

The short-term investments as of March 31, 2014 and December 31, 2013 were in inactive markets and, therefore, the estimated fair value is measured based on the Level 2 valuation hierarchy.

Inventories

Inventories	3 Months Ended
Inventories	Mar. 31, 2014
Inventory Disclosure [Abstract]	'
Inventories	'
	5. Inventories
	Inventories, net consist of the following (in thousands):


		MARCH 31,		DECEMBER 31,
		2014		2013
	Raw materials	$	5,913	$	5,355
	Work in progress		2,640		2,917
	Finished goods		4,284		3,394

		$	12,837	$	11,666

Net_Loss_Per_Share

Net Loss Per Share	3 Months Ended
Net Loss Per Share	Mar. 31, 2014
Earnings Per Share [Abstract]	'
Net Loss Per Share	'
	6. Net Loss Per Share
	Basic net loss per share, which excludes dilution, is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock, such as stock options, convertible notes, convertible preferred stock and warrants, result in the issuance of common stock which share in the losses of the Company.
	The following table sets forth the potential shares of common stock that are not included in the calculation of diluted net loss per share because to do so would be anti-dilutive as of the end of each period presented (in thousands). Such potentially dilutive shares are excluded when the effect would be to reduce the loss per share. The treasury stock method has been applied to determine the dilutive effect of warrants.


			31-Mar
			2014			2013
	Convertible preferred stock			—			8,504
	Convertible notes (1)			—			—
	Stock options outstanding			2,974			2,040
	Warrants to purchase convertible preferred stock			—			207
	Warrants to purchase common stock (2)			145			—

	(1)	As of March 31, 2013, the Company had approximately $46,037,000 in contingently convertible notes payable and related accrued interest for which the contingencies related to conversion had not been met until the IPO in August 2013. Therefore, it would have no dilutive or anti-dilutive impact until the contingency had been met in August 2013.
	(2)	In October 2012, the Company issued warrants to purchase a number of shares of common stock equal to 15% of the funded principal amount of the October 2012 Junior Secured Promissory Notes as defined in Note 10, divided by 70% of the value of common stock in a sale of the Company or a qualified initial public offering (qualified IPO), with an exercise price of 70% of the value of common stock in a sale of the Company or a qualified IPO. These warrants were contingently exercisable for which the contingencies related to exercise had not been met until the IPO in August 2013. Therefore, they would have no dilutive or anti-dilutive impact until the contingency had been met in August 2013.
	The numbers of shares of common stock issuable upon the exercise of warrants to purchase convertible preferred stock and upon the conversion of convertible preferred stock were at a ratio of one-to-one.


			THREE MONTHS ENDED
			MARCH 31
			2014			2013
			(In thousands, except per share data)
	Numerator:
	Net loss for basic and diluted net loss per share		$	(10,246	)	$	(10,749	)

	Denominator
	Weighted average shares outstanding for basic and diluted net loss per share			19,518			1,268

	Basic and diluted net loss per share:		$	(0.52	)	$	(8.48	)

Other_Assets

Other Assets	3 Months Ended
Other Assets	Mar. 31, 2014
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]	'
Other Assets	'
	7. Other Assets
	Other assets consist of the following (in thousands):


		MARCH 31,		DECEMBER 31,
		2014		2013
	Prepaid distribution fees	$	122	$	125
	Deferred financing costs, less current portion		102		148
	Deposits for equipment		76		256
	Deposits on equipment leases		177		177
	Other assets		162		100

		$	639	$	806

Accrued_Liabilities

Accrued Liabilities	3 Months Ended
Accrued Liabilities	Mar. 31, 2014
Payables And Accruals [Abstract]	'
Accrued Liabilities	'
	8. Accrued Liabilities
	Accrued liabilities consist of the following (in thousands):


			MARCH 31,			DECEMBER 31,
			2014			2013
	Accrued compensation		$	1,300		$	2,040
	Accrued severance			125			100
	Accrued expenses			1,462			1,570
	Accrued warranty costs			135			60
	Accrued inventory costs			18			610

			$	3,040		$	4,380

	On November 7, 2013, the Company announced that its Chief Financial Officer, Donald Glidewell, had decided to retire from the Company. To facilitate the transition, Mr. Glidewell agreed to remain as the Company’s Chief Financial Officer for up to five months while the Company searched for a successor Chief Financial Officer, and the Company entered into a transition agreement with Mr. Glidewell that provided, among other things, for continued vesting of his outstanding equity awards through his retirement date, which was March 25, 2014, and that upon his separation from the Company, Mr. Glidewell would be eligible to receive:

		•		an amount equal to six months of his then-current annual base salary payable monthly for a period of six months from his retirement date in the form of salary continuation;

		•		medical and dental coverage, plus disability and life insurance premiums, for a period of six months following his retirement; and

		•		full acceleration of vesting of his outstanding equity awards that are unvested as of his retirement date.
	The Company recorded accrued severance expenses in the amount of $125,000 and $100,000 as of March 31, 2014 and December 31, 2013, respectively, based on the terms of the transition agreement for salary, COBRA, and transition service related costs. See Note 11 for further discussion regarding the acceleration of vesting of Mr. Glidewell’s outstanding equity awards.
	The Company warrants the specifications and/or performance of its products through implied product warranties and has extended product warranties to qualifying customers on a contractual basis. The Company estimates the costs that may be incurred during the warranty period and records a liability in the amount of such costs at the time revenue is recognized. The Company’s estimate is based on historical experience and estimates of future warranty costs as a result of increasing usage of the Company’s products. The Company periodically assesses the adequacy of its recorded warranty liabilities and adjusts the amounts as necessary. Changes in the Company’s accrued warranty costs during the period are as follows (in thousands):


	Balance at December 31, 2013		$	60
	Warranties issued during the period			88
	Settlements made during the period			(13	)

	Balance at March 31, 2014		$	135

Factoring_and_Security_Agreeme

Factoring and Security Agreement	3 Months Ended
Factoring and Security Agreement	Mar. 31, 2014
Equity [Abstract]	'
Factoring and Security Agreement	'
	9. Factoring and Security Agreement
	On June 13, 2013, the Company entered into a factoring and security agreement (Factoring and Security Agreement) with a third-party that enabled the Company to sell its entire interest in certain accounts receivable up to $5,000,000. Under the Factoring and Security Agreement, 15% of the sales proceeds were to be held back by the purchaser until collection of such receivables. Such holdbacks were not considered legal securities, nor were they certificated. Upon the sale of the receivable, the Company did not maintain servicing. The purchaser may have required the Company to repurchase accounts receivable if (i) the payment was disputed by the account debtor, with the purchaser being under no obligation to determine the bona fides of such dispute; (ii) the account debtor had become insolvent or (iii) upon the effective date of the termination of the Factoring and Security Agreement. The purchaser would retain its security interest in any accounts repurchased by the Company. The Factoring and Security Agreement was secured by all of the Company’s personal property and fixtures, and proceeds thereof, including accounts receivable, inventory, equipment and general intangibles other than intellectual property. Upon sale of the receivable, the Company may have elected to set up a reserve where upon the cash for the sale remained with the third-party and the Company could draw on the available amount on the reserve account at any time. The Company elected to utilize the reserve account. On November 11, 2013, the Company terminated the Factoring and Security Agreement effective January 10, 2014.
	The Company accounted for sales of accounts receivable under the Factoring and Security Agreement as a secured borrowing in accordance with ASC 860, Transfers and Servicing (ASC 860). As of March 31, 2014, there was no balance in accounts receivable that was transferred under this arrangement. As of December 31, 2013, the Company had $479,000 included in accounts receivable that were transferred under this arrangement. As of March 31, 2014 and December 31, 2013, the Company did not have excess funds available on the reserve account and did not have secured borrowings outstanding under the arrangement.

Debt

Debt	3 Months Ended
Debt	Mar. 31, 2014
Debt Disclosure [Abstract]	'
Debt	'
	10. Debt
	Debt consists of the following (in thousands):


			MARCH 31,				DECEMBER 31,
			2014				2013
	Term Loan (Term Loan) bearing interest at 7.00% per annum which is payable monthly through April 2016. The Term Loan is collateralized by all of the Company’s inventories, chattel paper, accounts receivable, equipment and general intangibles (excluding certain financed equipment and intellectual property) pledged as collateral under the Term Loan, subordinated			279				309
	Promissory note bearing interest at 7.00% per annum which is payable monthly through November 2014, collateralized by all of the Company’s inventories, chattel paper, accounts receivable, equipment and general intangibles (excluding certain financed equipment and intellectual property), net of unamortized debt discount at March 31, 2014 of $1, subordinated			87				123
	Junior secured promissory notes (October 2012 and April 2013 Junior Secured Promissory Notes) bearing interest at 12.00% per annum which are payable monthly through October 2015, collateralized by substantially all of the Company’s assets, net of unamortized debt discount at March 31, 2014 of $381			12,069				12,005

	Debt			12,435				12,437
	Less current portion			(123	)			(157	)

			$	12,312			$	12,280

	The fair value of the Company’s outstanding debt obligations was $13,746,000 and $13,950,000 as of March 31, 2014 and December 31, 2013, respectively, which was estimated based on a discounted cash flow model using an estimated market rate of interest of 7.0% and is classified as Level 3 within the fair value hierarchy.
	Promissory Notes, Term Loan, Revolving Line of Credit and Credit Facility
	In March 2009, October 2010 and October 2011, the Company and the bank agreed to modify the terms of its existing revolving line of credit (Revolver). Under the modified terms of the Revolver, the Company’s borrowings under the Revolver were limited to 75% of qualifying accounts receivable with a maximum borrowing limit of $500,000. In March 2012, the Company entered into a change in terms agreement with the bank under which the existing Revolver was replaced by the Term Loan in the amount of $500,000 with a rate of 7.00% per annum, maturing April 1, 2016. The Company’s inventories, chattel paper, accounts receivable, equipment and general intangibles (excluding certain financed equipment and intellectual property) have been pledged as collateral under the Term Loan. The Revolver was terminated in March 2012.

	In March 2009, the Company borrowed $650,000 pursuant to a promissory note with a bank which bears interest at the rate of 7.00% per annum and is repayable in six monthly interest only payments starting May 1, 2009, followed by 60 equal monthly installments of $13,000 commencing November 1, 2009, with the final payment due on November 1, 2014. All of the Company’s inventories, chattel paper, accounts receivable, equipment and general intangibles (excluding certain financed equipment and any intellectual property) have been pledged as collateral for the promissory notes.
	On October 2, 2012, the Company borrowed $7,500,000 pursuant to senior notes (October 2012 Junior Secured Promissory Notes) with a group of lenders. The October 2012 Junior Secured Promissory Notes have an initial term of three years and can be extended for an additional two years in one year increments. During the initial three-year term, the October 2012 Junior Secured Promissory Notes bear interest at 12% per annum. If the term of the October 2012 Junior Secured Promissory Notes is extended an additional year, the interest rate increases to 13% during the fourth year. If the term of the October 2012 Junior Secured Promissory Notes is extended for an additional two years, the interest rate is 14% during the fifth year. Interest on the October 2012 Junior Secured Promissory Notes is payable monthly through the initial maturity date of the loan which is October 2, 2015 or through any extension period. The principal and all unpaid interest are due on the maturity date, as may be extended.
	As part of the terms of the October 2012 Junior Secured Promissory Notes, the Company is required to pay a fee of 5% of the funded principal amount to the agent that facilitated the borrowing and provides management of the relationship with the group of lenders (Agent Fee). This Agent Fee is payable within 30 days after all interest and principal have been paid. For each year the Company extends the maturity date of the October 2012 Junior Secured Promissory Notes beyond the initial term, the agent will receive an additional 1% fee based on the funded principal amount. The present value of the unpaid Agent Fee, based on 5% of the funded principal amount, or $261,000, as of the closing date of the October 2012 Junior Secured Promissory Notes was recorded as both deferred financing costs as a component of current and non-current other assets and non-current other liabilities. The amortization of the deferred financing costs and the accretion of the Agent Fee are recorded to interest expense over the term of the arrangement. As of March 31, 2014 and December 31, 2013, $519,000 and $502,000, respectively, of the Agent Fee, including the amounts relating to the additional funds received from the issuance of the April 2013 Junior Secured Promissory Notes discussed below, was recorded under non-current other liabilities. In addition, the Company incurred an additional $66,000 in financing-related costs, primarily legal fees. These costs were recorded as deferred financing costs as a component of current and non-current other assets and are being amortized to interest expense over the term of the arrangement. The October 2012 Junior Secured Promissory Notes are secured by the Company’s ownership interest in MMM LLC, a security interest in the assets of the Manufacturing Plant, and all of the Company’s other assets, subject to certain permitted liens.
	The Company also issued warrants (Common Stock Warrants) to the group of lenders to purchase a number of shares of common stock equal to 15% of the funded principal amount of the October 2012 Junior Secured Promissory Notes divided by 70% of the value of common stock in a sale of the Company or a qualified IPO, with such Common Stock Warrants having an exercise price of 70% of the value of common stock in a sale of the Company or a qualified IPO. The Common Stock Warrants would be automatically exercised immediately prior to expiration on the earlier to occur of a qualified IPO or a sale of the Company or the maturity of the October 2012 Junior Secured Promissory Notes. The October 2012 Junior Secured Promissory Notes could be prepaid six months after the initial funding date or earlier if a qualified IPO or a sale of the Company occurs. As the predominant settlement feature of the Common Stock Warrants is to settle a fixed monetary amount with a variable number of shares, the Common Stock Warrants were accounted for under ASC 480, Distinguishing Liabilities from Equity (ASC 480). Accordingly, the Common Stock Warrants were recorded at estimated fair value on their issuance date and were adjusted to their estimated fair value as of each reporting date with the change in estimated fair value recorded as a component of change in estimated fair value of financial instruments in the Company’s consolidated statements of operations. The fair value of the Common Stock Warrants at the date of issuance of $282,000 was recorded as a discount to the October 2012 Junior Secured Promissory Notes and is being amortized to interest expense over the term of the arrangement. Until the effective date of our IPO in August 2013, the Company estimated the fair value of the Common Stock Warrants using a PWERM valuation based on unobservable inputs, and, therefore, the Common Stock Warrants were considered to be Level 3 liabilities. Upon closing of the IPO, the exercise price of the Common Stock Warrants was determined to be $8.40 per share and the number of shares to be issued upon exercise of the warrants was no longer variable. As a result of the IPO, the Common Stock Warrants were considered to be indexed to the Company’s stock, and accordingly, the common stock warrants liability was reclassified and included in stockholders’ equity during the year ended December 31, 2013. In connection with the IPO, the Common Stock Warrants were exercised and accordingly, as of March 31, 2014, these warrants were no longer outstanding.
	The October 2012 Junior Secured Promissory Notes contained certain covenant requirements which included a requirement to maintain a minimum cash balance of the lesser of the April 2012 Senior Secured Promissory Note indebtedness or $5,000,000. The April 2012 Senior Secured Promissory Note was fully paid off in January 2013. The Company was also precluded from adding additional debt without lender approval unless such debt is subordinated to the October 2012 Junior Secured Promissory Notes and not more than $2,000,000. In the event of default on the October 2012 Junior Secured Promissory Notes, the lenders could declare the entire unpaid principal and interest immediately due and payable.

	On April 10, 2013 (Conversion Date), the Company entered an amendment to increase, by up to $5,000,000, the amount available under the terms of the October 2012 Junior Secured Promissory Notes. Under this amendment, an additional $4,950,000 in Notes were issued for $3,700,000 in cash consideration received and for the cancellation of $1,250,000 of the total principal balance of the October 2012 Subordinated Convertible Note (collectively, April 2013 Junior Secured Promissory Notes). The total amount borrowed under the amended loan agreement for the October 2012 Junior Secured Promissory Notes and the April 2013 Junior Secured Promissory Notes increased from $7,500,000 to $12,450,000 as of the Conversion Date. The accrued interest of $74,000 for the partially converted October 2012 Subordinated Convertible Note as of the Conversion Date would be repaid or converted on the applicable maturity date of the October 2012 Subordinated Convertible Note.
	In connection with the issuance of the April 2013 Junior Secured Promissory Notes, the Company issued additional warrants (Additional Common Stock Warrants) to purchase a number of shares of common stock equal to 20% of the funded principal amount of the April 2013 Junior Secured Promissory Notes divided by 70% of the value of common stock in a sale of the Company or a qualified IPO, with such Additional Common Stock Warrants to have an exercise price of 70% of the value of common stock in a sale of the Company or a qualified IPO. As the predominant settlement feature of the Additional Common Stock Warrants was to settle a fixed monetary amount with a variable number of shares, the Common Stock Warrants were accounted for under ASC 480. Accordingly, the Additional Common Stock Warrants were recorded at estimated fair value on their issuance date and were adjusted to their estimated fair value as of each reporting date with the change in estimated fair value recorded as a component of change in estimated fair value of financial instruments in the Company’s consolidated statements of operations. The fair value of the Additional Common Stock Warrants at the date of issuance was estimated to be $465,000. The Company estimated the fair value of the Additional Common Stock Warrants using a PWERM valuation based on unobservable inputs and, therefore, the Additional Common Stock Warrants were considered to be Level 3 liabilities. Upon closing of the IPO, the exercise price of the Common Stock Warrants was determined to be $8.40 per share and the number of shares to be issued upon exercise of the warrants was no longer variable. As a result of the IPO, the Common Stock Warrants were considered to be indexed to the Company’s stock, and accordingly, the common stock warrants liability was reclassified and included in stockholders’ equity during the year ended December 31, 2013.
	The debt holder who converted $1,250,000 principal balance of the October 2012 Subordinated Convertible Note (with a fair value of $1,360,000 on the date of conversion) also loaned an additional $2,500,000 in cash as part of the April 2013 Junior Secured Promissory Notes (collectively, the $3,750,000 Notes). The Company accounted for the conversion as an extinguishment of debt in accordance with ASC 470-50-40. The $1,360,000 fair value of the partially converted October 2012 Subordinated Convertible Note on the Conversion Date was derecognized and the fair value of the $3,750,000 Notes with the portion of the fair value of the Additional Common Stock Warrants issued to this debt holder on the date of issuance was recorded. The Company recorded the $49,000 excess of the total fair value of the $3,750,000 Notes and the related Additional Common Stock Warrants on the issuance date over total consideration received as a gain on extinguishment of debt in the accompanying consolidated statements of operations for the year ended December 31, 2013.
	The following table shows the consideration received, fair values of the notes and common stock warrants issued and calculation of the gain on extinguishment of debt for the $3,750,000 Notes (in thousands):


	Consideration received
	Fair Value of October 2012 Subordinated Convertible Note		$	1,360
	Cash			2,500

	Total Consideration Received (a)		$	3,860
	Notes and Warrants Issued
	Principal Balance of Notes Issued		$	3,750
	Debt Discount (1)			(291	)

	Fair Value of Notes Issued			3,459
	Fair Value of Additional Common Stock Warrants Issued			352

	Total Fair Value of Notes and Warrants Issued (b)		$	3,811

	Gain on Extinguishment of Debt (a - b)		$	49


	(1)	The amortization of this account is being recorded in interest expense in the consolidated statements of operations over the term of the arrangement.
	The remaining fair value to the Additional Common Stock Warrants of $113,000, net of the fair value of the Additional Common Stock Warrants issued of $352,000 related to the $3,750,000 Notes discussed above, was recorded as a debt discount to the April 2013 Junior Secured Promissory Notes and is being amortized to interest expense over the term of the arrangement.

	As a result of the amendment described above, the Company is also required to pay the Agent Fee, 5% of the $3,700,000 in cash received from the April 2013 Junior Secured Promissory Notes, under the same terms as the October 2012 Junior Secured Promissory Notes. In addition, the portion of the Agent Fee relating to the converted October 2012 Subordinated Convertible Note that would be due under the terms of the October 2012 Subordinated Convertible Note will be paid under the terms of the October 2012 and April 2013 Junior Secured Promissory Notes. The present value of the unpaid Agent Fee of $172,000, based on 5% of the funded principal amount of $4,950,000, as of the closing date of the April 2013 Junior Secured Promissory Notes was recorded as both deferred financing costs as a component of current and non-current other assets and non-current other liabilities. The amortization of the deferred financing costs and the accretion of the Agent Fee are being amortized to interest expense over the term of the arrangement.
	In addition, the Company incurred an additional $24,000 in financing-related costs, primarily legal fees. These costs were recorded as deferred financing costs as a component of current and non-current other assets and are being amortized to interest expense over the term of the arrangement.
	The amendment to the loan agreement also amended the interest provision applicable to the October 2012 and April 2013 Junior Secured Promissory Notes to allow any holder of the October 2012 and April 2013 Junior Secured Promissory Notes to request the Company to defer all interest due monthly to the applicable maturity date, and the optional prepayment provision applicable to the October 2012 and April 2013 Junior Secured Promissory Notes to allow the Company to repay the outstanding amount of the October 2012 and April 2013 Junior Secured Promissory Notes, either (i) with the written consent of the lender or the agent on such lenders’ behalf or (ii) without such consent provided that the Company pays the interest that would have been due from the prepayment date to the initial maturity date.
	Activity related to the October 2012 and April 2013 Junior Secured Promissory Notes from December 31, 2013 through March 31, 2014 consisted of the following (in thousands):


			DECEMBER 31,				ADDITIONS				AMORTIZATION			PRINCIPAL			MARCH 31,
			2013								OF DEBT			PAYMENTS			2014
											DISCOUNT
	Principal		$	12,450			$	—			$	—		$	—		$	12,450
	Debt discount related to issuance of common stock warrants (1)			(241	)			—				35			—			(206	)
	Discount related to the $3,750,000 Notes (1)			(204	)			—				29			—			(175	)

		$	12,005			$	—			$	64		$	—		$	12,069


(1)	The amortization of this account is included in interest expense in the consolidated statements of operations and as non-cash interest expense in the consolidated statements of cash flows.
On June 14, 2013, the Company entered into a credit facility agreement (June 2013 Credit Facility) with a group of lenders that were, or that were affiliated with, existing investors in the Company. Under the June 2013 Credit Facility, the lenders have committed to permit the Company to draw an aggregate of up to $5,000,000, and, subject to the Company’s obtaining additional commitments from lenders, such amount may be increased to up to $7,000,000. The June 2013 Credit Facility expires on June 30, 2014. During the term of the June 2013 Credit Facility, the Company could request from the lenders up to four advances, with each advance equal to one-quarter of each lender’s aggregate commitment amount. The Company would issue a promissory note in the principal amount of each such advance that would accrue interest at a rate of 10% per annum. The principal and all unpaid interest under the promissory notes would be due on the maturity date, and the Company could not prepay the promissory notes prior to the maturity date without consent of at least a majority in interest of the aggregate principal amount of the promissory notes then outstanding under the credit facility. In connection with the June 2013 Credit Facility, the Company paid a fee of 2% of the total commitment amount to the lenders. In addition, the Company incurred an additional $10,000 in financing-related costs, primarily legal fees. These costs were recorded as deferred financing costs as a component of current other assets and are being amortized to interest expense over the term of the arrangement.
In connection with the June 2013 Credit Facility, the Company issued warrants (June 2013 Warrants) to purchase a number of shares of common stock equal to 10% of the total committed amount of the June 2013 Credit Facility divided by 70% of the value of common stock in a sale of the Company or a qualified IPO, with such June 2013 Warrants to have an exercise price of 70% of the value of common stock in a sale of the Company or a qualified IPO. The June 2013 Warrants expire upon the earlier of June 14, 2023 or the sale of the Company. As the predominant settlement feature of the June 2013 Warrants was to settle a fixed monetary amount with a variable number of shares, the June 2013 Warrants were accounted for under ASC 480. Accordingly, the June 2013 Warrants were recorded at estimated fair value on their issuance date and were adjusted to their estimated fair value as of each reporting date with the change in estimated fair value recorded as a component of change in estimated fair value of financial instruments in the Company’s consolidated statements of operations. The fair value of the June 2013 Warrants at the date of issuance of $435,000 was recorded as a deferred financing cost as a current other asset and is being amortized to interest expense over the term of the arrangement. Until the effective date of the IPO in August 2013, the Company estimated the fair value of the June 2013 Warrants using a PWERM valuation based on unobservable inputs and, therefore, the June 2013 Warrants were considered to be Level 3 liabilities. Upon closing of the IPO, the exercise price of the June 2013 Warrants was determined to be $8.40 per share and the number of shares to be issued upon exercise of the warrants was no longer variable. As a result of the IPO, the June 2013 Warrants were considered to be indexed to the Company’s stock, and accordingly, the common stock warrants liability was reclassified and included in stockholders’ equity during the year ended December 31, 2013.
During the three months ended and as of March 31, 2014 and the year ended December 31, 2013, there were no amounts outstanding under the June 2013 Credit Facility.
The Company is also required to comply with certain affirmative and negative covenants under the debt agreements discussed above. In the event of default on the debt, the lender(s) may declare the entire unpaid principal and interest immediately due and payable. As of March 31, 2014, the Company was in compliance with all of the affirmative and negative covenants, and there were no events of default, as defined in the agreements, related to the debt.

ShareBased_Plans

Share-Based Plans	3 Months Ended
Share-Based Plans	Mar. 31, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Share-Based Plans	'
	11. Share-Based Plans
	As of March 31, 2014, there were 2,974,000 options outstanding and 1,128,000 share-based awards available for grant under the outstanding equity incentive plans.
	For the three months ended March 31, 2014, the Company recognized share-based compensation of $1,522,000, of which $444,000 related to the accelerated vesting of Donald Glidewell’s option awards. In connection with Mr. Glidewell’s retirement, the Company entered into a transition agreement with Mr. Glidewell (See Note 8) which provided, among other things, for the vesting of his outstanding equity awards through the retirement date. For the three months ended March 31, 2013, the Company recognized share-based compensation of $249,000.
	During the three months ended March 31, 2014, the Company granted 769,000 options at a weighted-average exercise price of $14.87 per share. During the three months ended March 31, 2014, 378,000 options were exercised at a weighted-average exercise price of $2.49 per share.

Commitments_and_Contingencies

Commitments and Contingencies	3 Months Ended
Commitments and Contingencies	Mar. 31, 2014
Commitments And Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	12. Commitments and Contingencies
	Commitments
	On September 9, 2013, the Company entered into a lease agreement for a new 28,700 square foot office and laboratory facility located in Davis, California. The initial term of the lease is for a period of 60 months commencing on the later of the date of substantial completion of initial improvements to the leased property, or May 1, 2014. The monthly base rent is $46,000 for the first 12 months with a 3% increase each year thereafter. The Company has the option to extend the lease term twice for a period of five years each. This agreement was subsequently amended in April 2014 (See Note 15).
	Contingencies
	The Company is subject to legal proceedings and claims that arise in the normal course of business. As of March 31, 2014, there were no current proceedings or litigation involving the Company that management believes would have a material adverse impact on its business, financial position, results of operations or cash flows.

Reverse_Stock_Split

Reverse Stock Split	3 Months Ended
Reverse Stock Split	Mar. 31, 2014
Text Block [Abstract]	'
Reverse Stock Split	'
	13. Reverse Stock Split
	On August 1, 2013, the Company amended and restated its certificate of incorporation to effect the conversion of its outstanding convertible preferred stock into common stock on a 1-for-1 basis followed immediately by a reverse split of shares of its common stock (including the common stock issued upon conversion of the convertible preferred stock) at a 1-for-3.138458 ratio (the “Reverse Stock Split”). The amendment also increased the number of shares of common stock authorized for issuance to 250,000,000 shares and the number of shares of preferred stock authorized for issuance to 20,000,000. The par value of the common stock and preferred stock was not adjusted as a result of the Reverse Stock Split.
	All issued and outstanding common stock, preferred stock, and warrants for common stock or preferred stock, and the related per share amounts contained in the condensed consolidated financial statements, have been retroactively adjusted to give effect to this Reverse Stock Split for all periods presented.

Related_Party_Transactions

Related Party Transactions	3 Months Ended
Related Party Transactions	Mar. 31, 2014
Related Party Transactions [Abstract]	'
Related Party Transactions	'
	14. Related Party Transactions
	Les Lyman, a member of the Company’s board of directors, is the chairman and significant indirect shareholder of The Tremont Group, Inc. During the three months ended March 31, 2014, The Tremont Group, Inc. purchased $320,000 of the Company’s products for further distribution and resale. As of March 31, 2014, the Company had outstanding accounts receivable due from The Tremont Group, Inc. of $1,230,000. Although the Company anticipates sales of its products to The Tremont Group, Inc. to continue through 2014, the Company cannot estimate the amount of those sales.
	During the three months ended March 31, 2014, the Company recorded revenue of $328,000 relating to license revenue recognized based on the terms of the Company’s agreements with Syngenta, an affiliate of one of our 5% stockholders. As of March 31, 2014, the Company had no outstanding accounts receivable due from Syngenta.

Subsequent_Events

Subsequent Events	3 Months Ended
Subsequent Events	Mar. 31, 2014
Subsequent Events [Abstract]	'
Subsequent Events	'
	15. Subsequent Events
	In April 2014, the Company entered into an agreement with a bank for a revolving line of credit, which allows the Company to borrow up to $5,000,000 with an interest rate of 1.5%. The line of credit is payable in full upon the bank’s demand, if no demand is made, it is payable in full in April 2015. Interest is payable monthly beginning in May 2014. In accordance with the terms of the agreement, the Company deposited $5,000,000 into a restricted deposit account with the bank as collateral.
	In April 2014, the Company entered into an agreement to amend the lease agreement for the new office and laboratory facility located in Davis, California. The amendment extends the commencement date to the later of August 1, 2014 or substantial completion of initial improvements. In addition, the square footage leased was reduced to 27,303 square feet and the monthly base rent was reduced to $44,000 per month for the first 12 months, with a 3% increase each year thereafter.
	Concurrent with this amendment in April 2014, the Company entered into a lease agreement with an affiliate of the landlord to lease 17,438 square feet of office and laboratory space in the same building complex in Davis, California. The initial term of the lease is for a period of 60 months commencing on the date of substantial completion of initial improvements. If the premises are not delivered by September 1, 2014, then the Company can terminate the lease at any time prior to January 1, 2015. The monthly base rent is $28,000 with a 3% increase each year thereafter.

Significant_Accounting_Policie1

Significant Accounting Policies (Policies)

3 Months Ended

Mar. 31, 2014

Accounting Policies [Abstract]

Basis of Presentation

Use of Estimates

Reclassifications

Certain prior period amounts have been reclassified to conform to the current year presentation. These reclassifications have no effect on previously reported net income.

Cash and Cash Equivalents

Short-Term Investments

Concentration of Credit Risk

For the three months ended March 31, 2014 and 2013, 5% and 14%, respectively, of the Company’s revenues were generated from international customers.

Customers with 10% or more of the Company’s total revenues consist of the following:

CUSTOMER

C (1)

For the three months ended March 31,

2014

2013

Represents less than 10% of total revenues

(1)

Represents related party revenues. See Note 14 for further discussion.

Customers with 10% or more of the Company’s outstanding accounts receivable consist of the following:

CUSTOMER

B (1)

March 31, 2014

December 31, 2013

(1)

Represents accounts receivable from related parties. See Note 14 for further discussion.

Inventories

Deferred Cost of Product Revenues

Acquisition

Land—Market approach based on similar, but not identical, transactions in the market. Adjustments to comparable sales are based on both the quantitative and qualitative data.

The following table summarizes the estimated fair value of the assets acquired as of the Acquisition Date, which were determined using Level 2 and 3 inputs as described above (in thousands):

JULY 19,

2012

Land

Building

314

Equipment

1,144

Assets acquired

1,459

Revenue Recognition

As of March 31, 2014 and December 31, 2013, the Company had current deferred product revenues of $824,000 and $1,016,000, respectively.

Research, Development and Patent Expenses

Recently Issued Accounting Pronouncements

There have been no new accounting pronouncements issued during the three months ended March 31, 2014 that are of significance, or potential significance, to the Company.

Significant_Accounting_Policie2

Significant Accounting Policies (Tables)	3 Months Ended
Significant Accounting Policies (Tables)	Mar. 31, 2014
Accounting Policies [Abstract]	'
Schedule of Concentration of Credit Risk Percentage	'
	Customers with 10% or more of the Company’s total revenues consist of the following:


			CUSTOMER			CUSTOMER			CUSTOMER			CUSTOMER			CUSTOMER			CUSTOMER			CUSTOMER			CUSTOMER
			A			B			C (1)			D			E			F			G			H
	For the three months ended March 31,
	2014			17	%		15	%		12	%		11	%		11	%			*			*			*
	2013			13	%			*			*			*			*		17	%		15	%		11	%

	*	Represents less than 10% of total revenues
	(1)	Represents related party revenues. See Note 14 for further discussion.
	Customers with 10% or more of the Company’s outstanding accounts receivable consist of the following:


			CUSTOMER			CUSTOMER			CUSTOMER			CUSTOMER
			A			B (1)			C			D
	March 31, 2014			16	%		15	%		11	%		10	%
	December 31, 2013			19	%		13	%		11	%		12	%

	(1)	Represents accounts receivable from related parties. See Note 14 for further discussion.
Summary of Estimated Fair Value of Assets Acquired	'
	The following table summarizes the estimated fair value of the assets acquired as of the Acquisition Date, which were determined using Level 2 and 3 inputs as described above (in thousands):


			JULY 19,
			2012
	Land		$	1
	Building			314
	Equipment			1,144

	Assets acquired		$	1,459

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	3 Months Ended
Fair Value Measurements (Tables)	Mar. 31, 2014
Fair Value Disclosures [Abstract]	'
Assets and Liabilities Measured at Fair Value on Recurring Basis	'
	The following table presents the Company’s financial assets and liabilities measured at fair value on a recurring basis as of March 31, 2014 and December 31, 2013 (in thousands):


		31-Mar-14
		TOTAL		LEVEL 1		LEVEL 2		LEVEL 3
	Assets
	Money market funds	$	5,069	$	5,069	$	—	$	—



		DECEMBER 31, 2013
		TOTAL		LEVEL 1		LEVEL 2		LEVEL 3
	Assets
	Money market funds	$	16,268	$	16,268	$	—	$	—

ShortTerm_Investments_Tables

Short-Term Investments (Tables)

3 Months Ended

Mar. 31, 2014

Investments Debt And Equity Securities [Abstract]

Amortized Cost and Estimated Fair Values of Short-Term Investments

The amortized cost and estimated fair values of short-term investments are summarized in the following table (in thousands):

MARCH 31, 2014

AMORTIZED

GROSS

ESTIMATED

COST

UNREALIZED

FAIR VALUE

GAINS

LOSSES

Securities Held-to-Maturity

Certificates of deposit, with maturities less than 1 year

2,664

—

2,664

DECEMBER 31, 2013

AMORTIZED

GROSS

ESTIMATED

COST

UNREALIZED

FAIR VALUE

GAINS

LOSSES

Securities Held-to-Maturity

Certificates of deposit, with maturities less than 1 year

13,677

—

)

13,673

Inventories_Tables

Inventories (Tables)	3 Months Ended
Inventories (Tables)	Mar. 31, 2014
Inventory Disclosure [Abstract]	'
Schedule of Inventories	'
	Inventories, net consist of the following (in thousands):


		MARCH 31,		DECEMBER 31,
		2014		2013
	Raw materials	$	5,913	$	5,355
	Work in progress		2,640		2,917
	Finished goods		4,284		3,394

		$	12,837	$	11,666

Net_Loss_Per_Share_Tables

Net Loss Per Share (Tables)	3 Months Ended
Net Loss Per Share (Tables)	Mar. 31, 2014
Earnings Per Share [Abstract]	'
Schedule of Anti-dilutive Securities Excluded from Computation of Diluted Net Loss Per Share	'
	The following table sets forth the potential shares of common stock that are not included in the calculation of diluted net loss per share because to do so would be anti-dilutive as of the end of each period presented (in thousands). Such potentially dilutive shares are excluded when the effect would be to reduce the loss per share. The treasury stock method has been applied to determine the dilutive effect of warrants.


			31-Mar
			2014			2013
	Convertible preferred stock			—			8,504
	Convertible notes (1)			—			—
	Stock options outstanding			2,974			2,040
	Warrants to purchase convertible preferred stock			—			207
	Warrants to purchase common stock (2)			145			—

	(1)	As of March 31, 2013, the Company had approximately $46,037,000 in contingently convertible notes payable and related accrued interest for which the contingencies related to conversion had not been met until the IPO in August 2013. Therefore, it would have no dilutive or anti-dilutive impact until the contingency had been met in August 2013.
	(2)	In October 2012, the Company issued warrants to purchase a number of shares of common stock equal to 15% of the funded principal amount of the October 2012 Junior Secured Promissory Notes as defined in Note 10, divided by 70% of the value of common stock in a sale of the Company or a qualified initial public offering (qualified IPO), with an exercise price of 70% of the value of common stock in a sale of the Company or a qualified IPO. These warrants were contingently exercisable for which the contingencies related to exercise had not been met until the IPO in August 2013. Therefore, they would have no dilutive or anti-dilutive impact until the contingency had been met in August 2013.
Computation of Common Shares Upon Exercise of Warrants and Basic and Diluted Net Loss Per Share	'
	The numbers of shares of common stock issuable upon the exercise of warrants to purchase convertible preferred stock and upon the conversion of convertible preferred stock were at a ratio of one-to-one.


			THREE MONTHS ENDED
			MARCH 31
			2014			2013
			(In thousands, except per share data)
	Numerator:
	Net loss for basic and diluted net loss per share		$	(10,246	)	$	(10,749	)

	Denominator
	Weighted average shares outstanding for basic and diluted net loss per share			19,518			1,268

	Basic and diluted net loss per share:		$	(0.52	)	$	(8.48	)

Other_Assets_Tables

Other Assets (Tables)	3 Months Ended
Other Assets (Tables)	Mar. 31, 2014
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]	'
Summary of Other Assets	'
	Other assets consist of the following (in thousands):


		MARCH 31,		DECEMBER 31,
		2014		2013
	Prepaid distribution fees	$	122	$	125
	Deferred financing costs, less current portion		102		148
	Deposits for equipment		76		256
	Deposits on equipment leases		177		177
	Other assets		162		100

		$	639	$	806

Accrued_Liabilities_Tables

Accrued Liabilities (Tables)	3 Months Ended
Accrued Liabilities (Tables)	Mar. 31, 2014
Payables And Accruals [Abstract]	'
Schedule of Accrued Liabilities	'
	Accrued liabilities consist of the following (in thousands):


		MARCH 31,			DECEMBER 31,
		2014			2013
	Accrued compensation	$	1,300		$	2,040
	Accrued severance		125			100
	Accrued expenses		1,462			1,570
	Accrued warranty costs		135			60
	Accrued inventory costs		18			610

		$	3,040		$	4,380

Schedule of Changes in Accrued Warranty Costs	'
	Changes in the Company’s accrued warranty costs during the period are as follows (in thousands):


	Balance at December 31, 2013	$	60
	Warranties issued during the period		88
	Settlements made during the period		(13	)

	Balance at March 31, 2014	$	135

Debt_Tables

Debt (Tables)	3 Months Ended
Debt (Tables)	Mar. 31, 2014
Debt Disclosure [Abstract]	'
Schedule of Debt	'
	Debt consists of the following (in thousands):


			MARCH 31,			DECEMBER 31,
			2014			2013
	Term Loan (Term Loan) bearing interest at 7.00% per annum which is payable monthly through April 2016. The Term Loan is collateralized by all of the Company’s inventories, chattel paper, accounts receivable, equipment and general intangibles (excluding certain financed equipment and intellectual property) pledged as collateral under the Term Loan, subordinated			279			309
	Promissory note bearing interest at 7.00% per annum which is payable monthly through November 2014, collateralized by all of the Company’s inventories, chattel paper, accounts receivable, equipment and general intangibles (excluding certain financed equipment and intellectual property), net of unamortized debt discount at March 31, 2014 of $1, subordinated			87			123
	Junior secured promissory notes (October 2012 and April 2013 Junior Secured Promissory Notes) bearing interest at 12.00% per annum which are payable monthly through October 2015, collateralized by substantially all of the Company’s assets, net of unamortized debt discount at March 31, 2014 of $381			12,069			12,005

	Debt			12,435			12,437
	Less current portion			(123	)		(157	)

			$	12,312		$	12,280

Consideration Received, Fair Values of Notes, Common Stock Warrants Issued and Calculation of the Gain on Extinguishment of Debt	'
	The following table shows the consideration received, fair values of the notes and common stock warrants issued and calculation of the gain on extinguishment of debt for the $3,750,000 Notes (in thousands):


	Consideration received
	Fair Value of October 2012 Subordinated Convertible Note		$	1,360
	Cash			2,500

	Total Consideration Received (a)		$	3,860
	Notes and Warrants Issued
	Principal Balance of Notes Issued		$	3,750
	Debt Discount (1)			(291	)

	Fair Value of Notes Issued			3,459
	Fair Value of Additional Common Stock Warrants Issued			352

	Total Fair Value of Notes and Warrants Issued (b)		$	3,811

	Gain on Extinguishment of Debt (a - b)		$	49


	(1)	The amortization of this account is being recorded in interest expense in the consolidated statements of operations over the term of the arrangement.
Activity Related to Secured Promissory Note	'
	Activity related to the October 2012 and April 2013 Junior Secured Promissory Notes from December 31, 2013 through March 31, 2014 consisted of the following (in thousands):


			DECEMBER 31,			ADDITIONS			AMORTIZATION		PRINCIPAL		MARCH 31,
			2013						OF DEBT		PAYMENTS		2014
									DISCOUNT
	Principal		$	12,450		$	—		$	—	$	—	$	12,450
	Debt discount related to issuance of common stock warrants (1)			(241	)		—			35		—		(206	)
	Discount related to the $3,750,000 Notes (1)			(204	)		—			29		—		(175	)

			$	12,005		$	—		$	64	$	—	$	12,069


	(1)	The amortization of this account is included in interest expense in the consolidated statements of operations and as non-cash interest expense in the consolidated statements of cash flows.

Summary_of_Business_Additional

Summary of Business - Additional Information (Detail) (USD $)	1 Months Ended	3 Months Ended
	Aug. 31, 2013	Mar. 31, 2014	Dec. 31, 2013
Organization Consolidation And Presentation Of Financial Statements [Abstract]	'	'	'
Date of incorporation	'	15-Jun-06	'
Accumulated deficit	'	($115,682,000)	($105,436,000)
Working capital	'	32,571,000	'
Cash, cash equivalents and short-term investments	'	$23,962,000	'
Reverse stock split	'1-for-3.138458	'	'

Significant_Accounting_Policie3

Significant Accounting Policies - Additional Information (Detail) (USD $)	3 Months Ended		12 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013	Jan. 19, 2012
Significant Accounting Policies [Line Items]	'	'	'	'
Reserves against inventories	$45,000	'	$45,000	'
Company acquired land, building and equipment	'	'	'	1,459,000
Transaction costs of acquisition	'	'	'	341,000
Fair value in excess of purchase price of the asset acquired	'	'	'	257,000
Interest expense	1,271,000	'	801,000	'
Current deferred product revenues	1,017,000	'	1,209,000	'
Deferred payments received	0	0	'	'
Recognized license revenues	45,000	48,000	'	'
Affiliate revenues percent	5.00%	'	'	'
Non-current deferred revenues	695,000	'	744,000	'
Deferred revenues related parties current	31,000	'	131,000	'
Deferred revenues related parties non-current	404,000	'	628,000	'
Research and development expenses	3,985,000	3,064,000	'	'
Patent expenses	297,000	219,000	'	'
Strategic collaboration and distribution agreements [Member]	'	'	'	'
Significant Accounting Policies [Line Items]	'	'	'	'
Current deferred product revenues	224,000	'	324,000	'
Non-current deferred revenues	1,099,000	'	1,372,000	'
Deferred revenues related parties current	31,000	'	131,000	'
Deferred revenues related parties non-current	404,000	'	628,000	'
Certificates of deposit [Member]	'	'	'	'
Significant Accounting Policies [Line Items]	'	'	'	'
Short-term investments original maturity description	'Short-term investments consist of certificates of deposit with original maturities less than one year but greater than three months which are classified as held-to-maturity.	'	'	'
Short-term investments original maturity period maximum	'1 year	'	'	'
Short-term investments original maturity period minimum	'3 months	'	'	'
Prepaid expenses and other current assets [Member]	'	'	'	'
Significant Accounting Policies [Line Items]	'	'	'	'
Deferred financing cost current	308,000	'	418,000	'
Sales revenue, net [Member] \| Customer concentration risk [Member] \| International [Member]	'	'	'	'
Significant Accounting Policies [Line Items]	'	'	'	'
Customers accounted for percentage of company's total revenues and accounts receivable	5.00%	14.00%	'	'
Grandevo and Regalia [Member] \| Sales revenue, net [Member] \| Product concentration risk [Member]	'	'	'	'
Significant Accounting Policies [Line Items]	'	'	'	'
Customers accounted for percentage of company's total revenues and accounts receivable	87.00%	97.00%	'	'
Revenue recognition [Member]	'	'	'	'
Significant Accounting Policies [Line Items]	'	'	'	'
Current deferred product revenues	824,000	'	1,016,000	'
Related party revenues [Member]	'	'	'	'
Significant Accounting Policies [Line Items]	'	'	'	'
Deferred payments received	328,000	33,000	'	'
Syngenta [Member]	'	'	'	'
Significant Accounting Policies [Line Items]	'	'	'	'
Recognized license revenues	$292,000	'	'	'
Affiliate revenues percent	5.00%	'	'	'
Maximum [Member]	'	'	'	'
Significant Accounting Policies [Line Items]	'	'	'	'
Receivables due period	'120 days	'	'	'
Maximum [Member] \| Sales revenue, net [Member] \| Customer concentration risk [Member]	'	'	'	'
Significant Accounting Policies [Line Items]	'	'	'	'
Customers accounted for percentage of company's total revenues and accounts receivable	10.00%	'	'	'

Significant_Accounting_Policie4

Significant Accounting Policies - Schedule of Concentration of Credit Risk Percentage (Detail) (Customer concentration risk [Member])

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Customer A [Member]

Customer B [Member]

Customer C [Member]

Customer D [Member]

Customer E [Member]

Customer F [Member]

Customer G [Member]

Customer H [Member]

Sales revenue, net [Member]

Accounts receivable [Member]

Sales revenue, net [Member]

Accounts receivable [Member]

Sales revenue, net [Member]

Accounts receivable [Member]

Sales revenue, net [Member]

Accounts receivable [Member]

Sales revenue, net [Member]

Concentration Risk [Line Items]

Customers accounted for percentage of company's total revenues and accounts receivable

17.00%

13.00%

16.00%

19.00%

15.00%

13.00%

12.00%

11.00%

10.00%

12.00%

11.00%

17.00%

15.00%

11.00%

Significant_Accounting_Policie5

Significant Accounting Policies - Schedule of Concentration of Credit Risk Percentage (Parenthetical) (Detail) (Maximum [Member], Customer concentration risk [Member], Sales revenue, net [Member])	3 Months Ended
	Mar. 31, 2014
Maximum [Member] \| Customer concentration risk [Member] \| Sales revenue, net [Member]	'
Concentration Risk [Line Items]	'
Customers accounted for percentage of company's total revenues and accounts receivable	10.00%

Significant_Accounting_Policie6

Significant Accounting Policies - Summary of Estimated Fair Value of Assets Acquired (Detail) (USD $)	Jul. 19, 2012
In Thousands, unless otherwise specified	Jul. 19, 2012
Business Combinations [Abstract]	'
Land	$1
Building	314
Equipment	1,144
Assets acquired	$1,459

Fair_Value_Measurements_Assets

Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) (Money market funds [Member], USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013
Assets	'	'
Assets at fair value	$5,069	$16,268
Level 1 [Member]	'	'
Assets	'	'
Assets at fair value	5,069	16,268
Level 2 [Member]	'	'
Assets	'	'
Assets at fair value	'	'
Level 3 [Member]	'	'
Assets	'	'
Assets at fair value	'	'

ShortTerm_Investments_Addition

Short-Term Investments - Additional Information (Detail) (Certificates of deposit [Member])	3 Months Ended
	Mar. 31, 2014
Certificates of deposit [Member]	'
Schedule of Investments [Line Items]	'
Short-term investments original maturity description	'Short-term investments consist of certificates of deposit with original maturities less than one year but greater than three months which are classified as held-to-maturity.
Short-term investments original maturity period, maximum	'1 year
Short-term investments original maturity period, minimum	'3 months

ShortTerm_Investments_Amortize

Short-Term Investments - Amortized Cost and Estimated Fair Values of Short-Term Investments (Detail) (Certificates of deposit [Member], USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013
Certificates of deposit [Member]	'	'
Schedule of Held-to-maturity Securities [Line Items]	'	'
Amortized Cost	$2,664	$13,677
Gross Unrealized Gains	'	'
Gross Unrealized Losses	'	-4
Estimated Fair value	$2,664	$13,673

Inventories_Schedule_of_Invent

Inventories - Schedule of Inventories (Detail) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013
Inventory Disclosure [Abstract]	'	'
Raw materials	$5,913	$5,355
Work in progress	2,640	2,917
Finished goods	4,284	3,394
Inventories, total	$12,837	$11,666

Net_Loss_Per_Share_Schedule_of

Net Loss Per Share - Schedule of Anti-dilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Detail)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Convertible preferred stock [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Anti-dilutive securities excluded from computation of earning per share	'	8,504
Convertible notes [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Anti-dilutive securities excluded from computation of earning per share	'	'
Stock options outstanding [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Anti-dilutive securities excluded from computation of earning per share	2,974	2,040
Warrants to purchase convertible preferred stock [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Anti-dilutive securities excluded from computation of earning per share	'	207
Warrants to purchase common stock [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Anti-dilutive securities excluded from computation of earning per share	145	'

Net_Loss_Per_Share_Schedule_of1

Net Loss Per Share - Schedule of Anti-dilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Parenthetical) (Detail) (USD $)	1 Months Ended
	Oct. 31, 2012	Mar. 31, 2013
Earnings Per Share [Abstract]	'	'
Contingently convertible notes payable	'	$46,037,000
Warrants issued to purchase a percentage of common stock	15.00%	'
Value of common stock in a sale of the Company or an initial public offering	70.00%	'
Percentage of exercise price on the value of common stock	70.00%	'

Net_Loss_Per_Share_Additional_

Net Loss Per Share - Additional Information (Detail)	1 Months Ended	3 Months Ended
Net Loss Per Share - Additional Information (Detail)	Aug. 31, 2013	Mar. 31, 2014
Earnings Per Share [Abstract]	'	'
Conversion of convertible preferred stock ratio	1	1

Net_Loss_Per_Share_Computation

Net Loss Per Share - Computation of Common Shares Upon Exercise of Warrants and Basic and Diluted Net Loss Per Share (Detail) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Numerator:	'	'
Net loss for basic and diluted net loss per share	($10,246)	($10,749)
Denominator	'	'
Weighted average shares outstanding for basic and diluted net loss per share	19,518	1,268
Basic and diluted net loss per share:	($0.52)	($8.48)

Other_Assets_Summary_of_Other_

Other Assets - Summary of Other Assets (Detail) (USD $)	Mar. 31, 2014	Dec. 31, 2013	Apr. 10, 2013
In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013	Apr. 10, 2013
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]	'	'	'
Prepaid distribution fees	$122	$125	'
Deferred financing costs, less current portion	102	148	24
Deposits for equipment	76	256	'
Deposits on equipment leases	177	177	'
Other assets	162	100	'
Other assets, total	$639	$806	'

Accrued_Liabilities_Schedule_o

Accrued Liabilities - Schedule of Accrued Liabilities (Detail) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013
Payables And Accruals [Abstract]	'	'
Accrued compensation	$1,300	$2,040
Accrued severance	125	100
Accrued expenses	1,462	1,570
Accrued warranty costs	135	60
Accrued inventory costs	18	610
Accrued liabilities, total	$3,040	$4,380

Accrued_Liabilities_Additional

Accrued Liabilities - Additional Information (Detail) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013
Payables And Accruals [Abstract]	'	'
Accrued severance expenses	$125	$100

Accrued_Liabilities_Schedule_o1

Accrued Liabilities - Schedule of Changes in Accrued Warranty Costs (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014
Payables And Accruals [Abstract]	'
Beginning Balance	$60
Warranties issued during the period	88
Settlements made during the period	-13
Ending Balance	$135

Factoring_and_Security_Agreeme1

Factoring and Security Agreement - Additional Information (Detail) (USD $)	1 Months Ended
	Jun. 13, 2013	Mar. 31, 2014	Dec. 31, 2013
Receivables [Abstract]	'	'	'
Sales of interest in accounts receivable	$5,000,000	'	'
Sales of interest in accounts receivables, percentage	15.00%	'	'
Accounts receivable transferred	'	'	$479,000

Debt_Schedule_of_Debt_Detail

Debt - Schedule of Debt (Detail) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013
Debt Instrument [Line Items]	'	'
Debt	$12,435	$12,437
Less current portion	-123	-157
Debt, less current portion	12,312	12,280
Term loan bearing interest at 7.00% [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt	279	309
Promissory note bearing interest at 7.00% [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt	87	123
October 2012 Junior secured promissory notes [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt	$12,069	$12,005

Debt_Schedule_of_Debt_Parenthe

Debt - Schedule of Debt (Parenthetical) (Detail) (USD $)	3 Months Ended			1 Months Ended	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2012	Mar. 31, 2009	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2014	Dec. 31, 2013
	Term loan bearing interest at 7.00% [Member]	Term loan bearing interest at 7.00% [Member]	Term loan bearing interest at 7.00% [Member]	Promissory note bearing interest at 7.00% [Member]	Promissory note bearing interest at 7.00% [Member]	Promissory note bearing interest at 7.00% [Member]	October 2012 Junior secured promissory notes [Member]	October 2012 Junior secured promissory notes [Member]
Debt Instrument [Line Items]	'	'	'	'	'	'	'	'
Debt instrument, interest rate	7.00%	7.00%	7.00%	7.00%	7.00%	7.00%	12.00%	12.00%
Debt instrument, payment terms	'Payable monthly through April 2016	'Payable monthly through April 2016	'	'Six monthly interest only payments starting May 1, 2009, followed by 60 equal monthly installments of $13,000 commencing November 1, 2009, with the final payment due on November 1, 2014.	'Payable monthly through November 2014	'Payable monthly through November 2014	'Payable monthly through October 2015	'Payable monthly through October 2015
Unamortized debt discount	'	'	'	'	$1	'	$381	'

Debt_Additional_Information_De

Debt - Additional Information (Detail) (USD $)

0 Months Ended

1 Months Ended

3 Months Ended

1 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

1 Months Ended

3 Months Ended

Apr. 10, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2013

Oct. 31, 2012

Apr. 10, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Apr. 10, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Apr. 10, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2012

Mar. 31, 2009

Mar. 31, 2014

Dec. 31, 2013

Common stock warrants [Member]

June 2013 credit facility [Member]

June 2013 warrants [Member]

October 2012 subordinated convertible note [Member]

April 2013 junior secured promissory note [Member]

Level 3 [Member]

Revolving Line of Credit [Member]

October 2012 Junior secured promissory notes [Member]

Term loan bearing interest at 7.00% [Member]

Promissory note bearing interest at 7.00% [Member]

Common stock warrants [Member]

Debt instrument maturity period year three [Member]

Extended fourth year [Member]

Extended fifth year [Member]

Installment

Debt Instrument [Line Items]

Fair value of debt

$13,746,000

$13,950,000

Estimated market rate of interest

7.00%

Percentage of borrowings limited to qualifying accounts receivable

75.00%

Line of credit facility maximum borrowing limit

7,000,000

500,000

Debt instrument, interest rate

12.00%

13.00%

14.00%

7.00%

Debt instrument maturity date

1-Apr-16

1-Nov-14

Debt instrument borrowing amount

7,500,000

650,000

Debt instrument, payment terms

'Payable monthly through October 2015

'Payable monthly through April 2016

'Six monthly interest only payments starting May 1, 2009, followed by 60 equal monthly installments of $13,000 commencing November 1, 2009, with the final payment due on November 1, 2014.

'Payable monthly through November 2014

Number of monthly installments

Amount paid in each installment

13,000

Installment payment commencing date

1-Nov-09

Debt instrument borrowing terms

'The October 2012 Junior Secured Promissory Notes have an initial term of three years and can be extended for an additional two years in one year increments. During the initial three-year term, the October 2012 Junior Secured Promissory Notes bear interest at 12% per annum. If the term of the October 2012 Junior Secured Promissory Notes is extended an additional year, the interest rate increases to 13% during the fourth year. If the term of the October 2012 Junior Secured Promissory Notes is extended for an additional two years, the interest rate is 14% during the fifth year. Interest on the October 2012 Junior Secured Promissory Notes is payable monthly through the initial maturity date of the loan which is October 2, 2015 or through any extension period. The principal and all unpaid interest are due on the maturity date, as may be extended.

Agent fee percentage

5.00%

Additional fee percentage

1.00%

Unpaid agent fee

172,000

261,000

Fees amount

519,000

502,000

Additional costs related to legal fees

66,000

Warrants issued to purchase common stock funded principal percentage

15.00%

Value of common stock in a sale of the Company or an initial public offering

70.00%

Fair value of Common Stock Warrants

282,000

Exercise price of the Common Stock Warrants

8.4

Common Stock Warrants outstanding

Covenant requirements minimum cash balance

5,000,000

Additional debt cash balance

2,000,000

Increase in amount available under loan agreement

5,000,000

Additional debt issued under amendment

4,950,000

Debt issued in cash consideration

3,700,000

Debt issued in cash consideration for cancellation of principal balance

1,250,000

Amount borrowed under amended loan agreement

7,500,000

12,450,000

Accrued interest on promissory notes

74,000

Warrants exercise price percentage

70.00%

Exercise price of warrants as percentage of common stock

70.00%

Common stock warrants issued to purchase common stock percentage

20.00%

10.00%

Fair value of Common Stock Warrants

465,000

Convertible debt instrument, face value

46,037,000

1,250,000

Convertible debt, fair value

1,360,000

3,459,000

Debt instrument, additional borrowings

2,500,000

Promissory notes issued

3,750,000

Gain on extinguishment of debt

49,000

Debt discount

113,000

Fair value of Additional Common Stock Warrants issued

352,000

Funds borrowed

3,700,000

4,950,000

Additional unpaid Agent Fee, percentage

5.00%

Deferred finance costs

24,000

102,000

148,000

Amount permit to draw

5,000,000

Credit facility expiry date

30-Jun-14

Credit facility accrued interest

10.00%

Credit facility fee paid

2.00%

Credit facility financing-related costs and primarily legal fees

10,000

Warrants expire date

14-Jun-23

Fair value of the Warrants at the date of issuance as deferred financing cost

435,000

Outstanding amounts

Debt_Consideration_Received_Fa

Debt - Consideration Received, Fair Values of Notes, Common Stock Warrants Issued and Calculation of the Gain on Extinguishment of Debt (Detail) (USD $)	1 Months Ended	3 Months Ended
In Thousands, unless otherwise specified	Apr. 10, 2013	Mar. 31, 2014
Consideration received	'	'
Total Consideration Received	'	$3,860
Notes and Warrants Issued	'	'
Total Fair Value of Notes and Warrants Issued	'	3,811
Gain on extinguishment of debt	'	49
October 2012 subordinated convertible note [Member]	'	'
Consideration received	'	'
Fair Value of Notes	1,360	1,360
Notes and Warrants Issued	'	'
Fair Value of Notes	1,360	1,360
April 2013 junior secured promissory note [Member]	'	'
Consideration received	'	'
Fair Value of Notes	'	3,459
Cash	2,500	2,500
Notes and Warrants Issued	'	'
Principal Balance of Notes Issued	'	3,750
Debt Discount	'	-291
Fair Value of Notes	'	3,459
Fair value of Additional Common Stock Warrants issued	$352	$352

Debt_Activity_Related_to_Secur

Debt - Activity Related to Secured Promissory Note (Detail) (USD $)	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2014	Mar. 31, 2014	Mar. 31, 2014	Mar. 31, 2014
In Thousands, unless otherwise specified			October 2012 Junior secured promissory notes [Member]	October 2012 Junior secured promissory notes [Member]	October 2012 Junior secured promissory notes [Member]	October 2012 Junior secured promissory notes [Member]
				Debt discount related to issuance of common stock warrants [Member]	Discount related to the $3,750,000 Notes [Member]	Principal [Member]
Debt Instrument [Line Items]	'	'	'	'	'	'
Debt, beginning balance	$12,435	$12,437	$12,005	($241)	($204)	$12,450
Additions	'	'	'	'	'	'
Amortization of debt discount	'	'	64	35	29	'
Debt, ending balance	12,435	12,437	12,069	-206	-175	12,450
Principal payments	'	'	'	'	'	'

Debt_Activity_Related_to_Secur1

Debt - Activity Related to Secured Promissory Note (Parenthetical) (Detail) (October 2012 Junior secured promissory notes [Member], USD $)	Mar. 31, 2014
October 2012 Junior secured promissory notes [Member]	'
Debt Instrument [Line Items]	'
Promissory notes, issued	$3,750,000

ShareBased_Plans_Additional_In

Share-Based Plans - Additional Information (Detail) (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'	'
Stock options outstanding	2,974,000	'
Share-based awards available for grant	1,128,000	'
Share-based compensation expense	$1,522	$249
Accelerated vesting of Donald Glidewell's	444,000	'
Number of options granted	769,000	'
Weighted-average exercise price per share	$14.87	'
Number of options exercised	378,000	'
Weighted-average exercise price per share, exercised	$2.49	'

Commitments_and_Contingencies_

Commitments and Contingencies - Additional Information (Detail) (USD $)	0 Months Ended	3 Months Ended
	Sep. 09, 2013	Mar. 31, 2014
	sqft	Mar. 31, 2014
Operating Leased Assets [Line Items]	'	'
Office facility lease agreement	28,700	'
Lease agreement period	'60 months	'
Monthly base rent	$46,000	'
Percentage of annual increase in base rent	3.00%	'
Lease renewal period	'5 years	'
Legal proceedings	'	$0
Office and laboratory [Member]	'	'
Operating Leased Assets [Line Items]	'	'
Lease start date	9-Sep-13	'

Reverse_Stock_Split_Additional

Reverse Stock Split - Additional Information (Detail)	1 Months Ended	3 Months Ended
In Thousands, unless otherwise specified	Aug. 31, 2013	Mar. 31, 2014	Dec. 31, 2013
Equity [Abstract]	'	'	'
Conversion of convertible preferred stock ratio	1	1	'
Reverse stock split	'1-for-3.138458	'	'
Reverse stock split, ratio	3.138458	'	'
Increased number of shares of common stock authorized for issuance	250,000	250,000	250,000
Increased number of shares of preferred stock authorized for issuance	20,000	20,000	20,000

Related_Party_Transactions_Add

Related Party Transactions - Additional Information (Detail) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Related Party Transaction [Line Items]	'	'
Products purchased for further distribution and resale	$648,000	$309,000
Affiliate revenues percent	5.00%	'
Tremont Group, Inc. [Member]	'	'
Related Party Transaction [Line Items]	'	'
Products purchased for further distribution and resale	320,000	'
Outstanding accounts receivable due	1,230,000	'
Syngenta [Member]	'	'
Related Party Transaction [Line Items]	'	'
Outstanding accounts receivable due	0	'
License revenue recognized	$328,000	'
Affiliate revenues percent	5.00%	'

Subsequent_Events_Additional_I

Subsequent Events - Additional Information (Detail) (USD $)	0 Months Ended		1 Months Ended			1 Months Ended
	Sep. 09, 2013	Sep. 09, 2013	Apr. 30, 2014	Apr. 30, 2014	Apr. 30, 2014	Apr. 30, 2014
	sqft	Office and laboratory [Member]	Subsequent Event [Member]	Subsequent Event [Member]	Subsequent Event [Member]	Subsequent Event [Member]
			sqft	Office and laboratory [Member]	Revolving Line of Credit [Member]	Amendment [Member]
						sqft
Subsequent Event [Line Items]	'	'	'	'	'	'
Debt instrument, maximum borrowing capacity	'	'	'	'	$5,000,000	'
Debt instrument, interest rate	'	'	'	'	1.50%	'
Restricted deposit	'	'	'	'	5,000,000	'
Amendment agreement commencement date	'	'	'	'	'	1-Aug-14
Office facility lease agreement	28,700	'	17,438	'	'	27,303
Initial base rent term	'	'	'	'	'	'12 months
Monthly base rent	$46,000	'	$28,000	'	'	$44,000
Percentage of annual increase in base rent	3.00%	'	3.00%	'	'	3.00%
Lease agreement period	'	'	'60 months	'	'	'
Lease start date	'	9-Sep-13	'	30-Apr-14	'	'